🛡️ Cupid Limited

📋 About Cupid Limited

Cupid Limited is a Nashik-based, BSE-listed Indian company that has quietly built a powerful niche in the global sexual health and contraceptives market. Founded in 1993, Cupid manufactures male condoms, female condoms, lubricant gels, and water-based personal care products — supplying not just to India’s domestic market but to international organisations including UNFPA, WHO-affiliated procurement agencies, and various government health ministries across Africa, Latin America, and Asia.

What truly sets Cupid apart is its distinction as India’s only WHO-prequalified female condom manufacturer — a certification that is notoriously difficult to obtain and gives the company a near-monopoly moat in this specialised segment. The company also supplies male condoms under India’s National Health Mission, making institutional procurement a core revenue driver.

Over the past decade, Cupid has steadily diversified beyond contraceptives into personal lubricants and wellness products, positioning itself as a broader sexual wellness company with export ambitions. With a lean manufacturing setup in Nashik and a growing international order book, Cupid has all the hallmarks of a niche compounder — small, focused, and deeply entrenched in markets where regulatory barriers protect its position. 🌍

🌐 Official website: Cupid Limited Official Website

🚀 Expansion Plans

Cupid Limited’s growth runway looks compelling as the company executes on multiple fronts simultaneously. Here’s what the expansion story looks like heading into 2026 and beyond:

• 📦 Capacity Expansion: Cupid has been progressively scaling its Nashik manufacturing facility to handle larger international tender volumes. The company has invested in additional condom production lines to meet the surge in demand from UN procurement agencies and African government health programs. Management has indicated a clear intent to double production capacity over the next 3–4 years.
• 🌍 Geographic Diversification: While Africa remains the largest export destination for female condoms, Cupid is actively pursuing orders from Southeast Asian and Latin American markets. The company’s WHO prequalification status acts as a golden passport for entering new geographies where institutional buyers mandate global health certifications.
• 💊 Product Portfolio Broadening: Beyond condoms, Cupid is expanding into lubricant gels, personal wellness products, and OTC health items. This diversification is critical to reduce revenue lumpiness caused by tender-based income cycles and build a more predictable revenue stream.
• 🏬 Retail & D2C Push: The company is gradually building brand presence in modern trade and e-commerce channels in India, tapping the fast-growing domestic sexual wellness market — estimated to grow at 12–15% CAGR over the next five years.
• 🤝 Strategic Partnerships: Cupid is reportedly in discussions with global NGOs and bilateral health organisations to secure long-term supply agreements, which would significantly de-risk the lumpy nature of one-off tender wins and provide more earnings visibility.

The combined effect of capacity ramp-up, geographic expansion, and product diversification makes Cupid a company with a potentially long growth runway — even if the near-term valuation demands careful consideration. 🚀

✅ Key Positives

• ✅ Unmatched Regulatory Moat: Cupid is the only Indian company with WHO prequalification for female condoms. This certification takes years and significant investment to obtain, making it an almost insurmountable barrier for new entrants. Competitors simply cannot walk in and steal this business overnight.
• ✅ Debt-Light Balance Sheet: With a Debt-to-Equity ratio of just 0.12, Cupid runs an essentially debt-free operation. This financial prudence gives the company flexibility to invest in growth without the burden of interest payments eating into profitability — a hallmark of quality small-cap businesses.
• ✅ Excellent Capital Efficiency: A ROCE of 33.9% and ROE of 27.6% tell us that Cupid generates exceptional returns on the capital deployed. These numbers are well above the cost of capital, meaning every rupee reinvested in the business creates substantial value for shareholders. 💰
• ✅ Sticky Government & Institutional Clients: Revenue from UNFPA, National Health Mission, and bilateral aid agencies is relationship-driven and repeat in nature. Once Cupid qualifies as a preferred supplier, switching costs for the buyer are high due to requalification requirements.
• ✅ Growing Global Sexual Wellness Market: The global contraceptive market is projected to grow steadily, driven by rising awareness, government family planning initiatives, and increasing female empowerment programs. Cupid sits at the intersection of healthcare and social development — two themes that attract long-term institutional funding.
• ✅ Consistent Earnings Growth: With an EPS growth rate of approximately 21%, Cupid has demonstrated a reliable ability to grow profits year-on-year, even through challenging macro environments. This consistency is rare in small-cap companies and signals strong operational execution.
• ✅ Export-Oriented Revenue Mix: A significant portion of Cupid’s revenue comes from exports, which provides a natural hedge against domestic demand slowdowns and benefits from a weaker rupee environment. 🌐

⚠️ Key Concerns

• ⚠️ Extreme Valuation Stretched: At a PE of 306x and a PB of 93.1x, the stock is priced for near-perfection. Any earnings disappointment could trigger a sharp correction. The intrinsic value of ₹39 versus the current market price of ₹312 represents a significant valuation gap. 🔴
• ⚠️ Revenue Concentration Risk: Heavy reliance on government and institutional tenders means revenue can be lumpy. A single delayed or lost tender can significantly dent quarterly performance and market sentiment.
• ⚠️ Small Company Scale: Despite its moat, Cupid’s absolute revenue base remains small, making it vulnerable to operational disruptions, management bandwidth constraints, and the challenges of scaling internationally against well-funded global players.
• ⚠️ Promoter Holding Below 50%: At 46.24%, promoter holding is below the comfort zone for many investors and could raise governance attention in the future.

🔍 SWOT Analysis

Cupid Limited’s SWOT profile reveals a company with a rare and defensible competitive moat — its WHO prequalification for female condoms is the crown jewel — yet one that carries meaningful strategic vulnerabilities. The strengths lie in regulatory barriers, capital efficiency, and international institutional relationships. Weaknesses centre on revenue lumpiness and a current extreme valuation premium. Opportunities abound in global health spending growth, African market expansion, and India’s domestic wellness boom. However, threats from policy budget cuts, currency headwinds, and global competitive bidding should not be underestimated. Investors must balance the compelling moat story against the demanding price being paid. ⚖️

* SWOT is based on publicly available information and analyst estimates. Not a buy/sell recommendation.

📈 Profit & Loss (Last 5 Years)

Cupid Limited has delivered consistent revenue and profit growth over the past five financial years, driven by a combination of rising export tender wins, capacity additions, and gradual product diversification. Revenue has grown from approximately ₹98 Cr in FY22 to an estimated ₹205 Cr in FY26E, while net profit has expanded from roughly ₹12 Cr to an estimated ₹34 Cr over the same period — reflecting healthy margin expansion alongside volume growth. The profit CAGR over this period stands at an impressive ~23%, validating the company’s operational leverage and pricing discipline in institutional markets. 📊

* Estimated figures in ₹ Crores. Source: Annual reports & public disclosures. Not guaranteed to be accurate.

🔴 Risk Factors

• 🔴 Valuation Risk: At a PE of 306x and market price of ₹312 against an intrinsic value of ₹39, the stock carries extreme valuation risk. Any growth deceleration could lead to significant price correction.
• 🔴 Tender Concentration Risk: Loss of one or two large international tenders (UNFPA, bilateral programs) could cause revenue to fall sharply in any given year, leading to earnings volatility.
• 🔴 Raw Material Price Risk: Natural latex — the primary raw material for condoms — is subject to global commodity price fluctuations. A sharp spike in latex prices without corresponding price increases in tender contracts could compress margins significantly.
• 🔴 Currency Risk: Export revenues denominated in USD/EUR are subject to foreign exchange volatility. A sharp rupee appreciation could erode the realised value of export contracts.
• 🔴 Regulatory & Compliance Risk: WHO prequalification must be periodically renewed and maintained through stringent audits. Any compliance failure could result in loss of prequalified status — effectively destroying the company’s primary export moat overnight.
• 🔴 Competition from Global Players: Large global manufacturers from China, Malaysia, and Thailand participate aggressively in price-sensitive tender bidding, creating ongoing pressure on bid prices and margins.
• 🔴 Small Market Cap Liquidity Risk: Despite the headline market cap, daily trading volumes can be thin, making entry and exit at desired prices challenging for larger investors. ⚠️

📊 Value Investing Snapshot

^* Revenue CAGR (3Y) and Profit CAGR (3Y) are analyst estimates based on publicly available financial data and management commentary. All other metrics reflect verified financial data as of the research date.

🟢 Green = Strong/Attractive  |  🟡 Yellow = Moderate  |  🔴 Red = Weak/Caution
Mkt Cap: 🟢 < ₹10,000 Cr   🟡 ₹10,000 Cr – ₹1,00,000 Cr   🔴 > ₹1,00,000 Cr (1 lakh crore)

🏆 About Futurecaps

Futurecaps is a SEBI-registered investment research platform trusted by thousands of retail investors across India for in-depth, unbiased stock research and multibagger recommendations. Our team of experienced analysts digs deep into financial statements, business models, and competitive dynamics to identify high-conviction investment opportunities before the crowd catches on. Whether you’re a seasoned value investor or just starting your wealth-creation journey, Futurecaps provides the rigorous research you need — in plain, friendly language that actually makes sense. Our track record of identifying multibagger stocks early has made us one of India’s most followed independent research communities. 🏆💰

💡 About Value Investing

Value investing is the timeless discipline of buying businesses for less than what they’re truly worth — and patiently waiting for the market to recognise that gap. Pioneered by Benjamin Graham and perfected by Warren Buffett, value investing focuses on intrinsic value, margin of safety, and long-term compounding rather than short-term price chasing. The key is identifying quality businesses trading at a discount to their intrinsic value — giving you a buffer against downside risk. Want to calculate the intrinsic value of any stock yourself? Try the Futurecaps Intrinsic Value Calculator — it’s free and incredibly easy to use! 💡📊